
■ IAP Symposium 1

International Consensus on Autoimmune Pancreatitis

JULY 11 (8:30–11:30) Room 1

Moderators: Tooru Shimosegawa (Tohoku University, Japan)

Suresh T. Chari (Mayo Clinic, USA)

◎AIP: Buildup of Consensus

1. How Should be the International Consensus Criteria?

..... Tooru Shimosegawa (*Division of Gastroenterology, Tohoku University
Graduate School of Medicine, Japan*)

..... Suresh T. Chari (*Division of Gastroenterology and Hepatology, Mayo Clinic, USA*)

2. Overview of AIP: Agreement and Disagreement in Hawaii

..... Kazuichi Okazaki (*Department of Gastroenterology and Hepatology, Kansai
Medical University, Japan*)

..... Guenter Klöppel (*Institut für Pathologie des Technischen Universität München, Germany*)

3. Should Diffuse and Focal Types be Distinguished in the Diagnostic Procedure?

..... Kazuichi Okazaki (*Department of Gastroenterology and Hepatology, Kansai
Medical University, Japan*)

..... Luca Frulloni (*Department of Biomedical and Surgical Sciences, University of
Verona, Italy*)

4. Imaging—Is ERCP Essential? Can it be Replaced with MRCP?

..... Terumi Kamisawa (*Department of Gastroenterology, Tokyo Metropolitan
Cancer and Infectious Diseases Center, Komagome
Hospital, Japan*)

..... Myung-Hwan Kim (*Department of Gastroenterology, University of Ulsan
College of Medicine, Asan Medical Center, Korea*)

..... Luca Frulloni (*Department of Biomedical and Surgical Sciences, University of
Verona, Italy*)

5. Serology—Are IgG and Autoantibodies Necessary?

..... Shigeyuki Kawa (*Shinshu University, Center for Health Safety and
Environmental Management, Japan*)

..... Suresh T. Chari (*Division of Gastroenterology and Hepatology, Mayo Clinic, USA*)

6. OOIs—Should They be Included in the Criteria?

..... Shigeyuki Kawa (*Shinshu University, Center for Health Safety and Environmental Management, Japan*)

..... Suresh T. Chari (*Division of Gastroenterology and Hepatology, Mayo Clinic, USA*)

7. Histology—Can LPSP be Differentiated from IDC?

..... Lizhi Zhang (*Division of Anatomic Pathology, Mayo Clinic, USA*)

..... Kenji Notohara (*Department of Pathology, Kurashiki Central Hospital, Japan*)

..... Mari Mino-Kenudson (*Gastrointestinal Pathology Service, Massachusetts General Hospital, USA*)

..... Guenter Klöppel (*Institut für Pathologie des Technischen Universität München, Germany*)

8. Diagnostic Use of Steroid—What is the Indication?

..... Tooru Shimosegawa (*Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan*)

..... Myung-Hwan Kim (*Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Korea*)

© Proposal of Consensus Criteria

Proposal of International Consensus Criteria for AIP (Draft)

..... Terumi Kamisawa (*Department of Gastroenterology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Japan*)

Comment to the Consensus Criteria

..... Myung-Hwan Kim (*Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center, Korea*)

..... Suresh T. Chari (*Division of Gastroenterology and Hepatology, Mayo Clinic, USA*)

..... Markus M. Lerch (*Department of Medicine A, Greifswald University, Germany*)

© Overall Discussion

*Presenters' abstracts are not available for this session. Please refer to moderators' remark on Page 256.

■ IAP Symposium 2

The Current Status of Pancreatic Neuroendocrine Tumors

JULY 11 (8:30–11:30) Room 2

Moderators: Tetsuhide Ito (Kyushu University, Japan)

Robert T. Jensen (National Institutes of Health, USA)

Sponsored by Novartis Pharma K.K.

IPSY2-1 Changing Clinical Practice for Pancreatic Neuroendocrine Tumors

..... Masayuki Imamura (*Director Osaka Saiseikai Noe Hospital, Honorary Professor Kyoto University, Japan*)

IPSY2-2 Epidemiology and Clinicopathological Features of PNET

..... Bertram Wiedenmann (*Charite Medical School, Berlin, Germany*)

IPSY2-3 Role of Angiogenesis in Pancreatic Neuroendocrine Tumors (PNET)

..... Eric Raymond (*Department of Medical Oncology, Beaujon University Hospital, France*)

IPSY2-4 Diagnostic Procedure for PNET

..... Hisato Igarashi (*Department of Medicine and Bioregulatory Science, Graduate School of Medical Science, Kyushu University, Japan*)

Current Therapeutic Strategy for PNET

IPSY2-5 Determinants of Resection for Pancreatic Neuroendocrine Tumors

..... Ryuichiro Doi (*Department of Surgery, Japanese Red Cross Otsu Hospital, Japan*)

IPSY2-6 Surgical Treatment of Hepatic Metastasis of Pancreatic Neuroendocrine Tumor

..... Takao Ohtsuka (*Department of Surgery and Oncology, Kyushu University, Japan*)

IPSY2-7 Medical Treatment of Advanced Pancreatic Neuroendocrine Tumors

..... Takuji Okusaka (*Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Japan*)

IPSY2-8 Sandostatin Treatment for PNET

..... Tetsuhide Ito (*Department of Medicine and Bioregulatory
Science, Graduate School of Medical
Sciences, Kyushu University, Japan*)

IPSY2-9 Overview and Future in PNET

..... Robert T. Jensen (*Digestive Diseases Branch, National Institutes of
Health, USA*)

■ IAP Symposium 3

International Consensus on Cystic Neoplasms of the Pancreas

JULY 12 (9:00–12:00) Room 1

Moderators: Masao Tanaka (Kyushu University, Japan)

Carlos Fernandez-del Castillo (Massachusetts General Hospital, USA)

- 1. Classification of IPMNs by Duct Type: Is the Mixed Category a Separate Entity?**
Presenter: Carlos Fernandez-del Castillo (*Massachusetts General Hospital, USA*)
Discussants: Kenji Yamao (*Department of Gastroenterology, Aichi Cancer Center Hospital, Japan*)
Jin-Young Jang (*Division of Hepatobiliary–Pancreatic Surgery, Department of Surgery, Seoul National University College of Medicine, Korea*)
- 2. Can Branch Duct IPMN be Distinguished Preoperatively from MCN and Other Pancreatic Cysts? What is the Role of Cyst Fluid Analysis?**
Presenter #1: C. Max Schmidt (*Department of Surgery, Indiana University School of Medicine, USA*)
Presenter #2: Martha Bishop Pitman (*Pathology, Massachusetts General Hospital, Harvard Medical School, USA*)
Discussants: Wataru Kimura (*Department of Gastroenterological and General Surgery, Yamagata University Faculty of Medicine, Japan*)
Kenji Yamao (*Department of Gastroenterology, Aichi Cancer Center Hospital, Japan*)
- 3. Criteria for Resection of Branch Duct IPMNs: Is the Sendai Recommendation Safe?**
Presenter: Jin-Young Jang (*Division of Hepatobiliary–Pancreatic Surgery, Department of Surgery, Seoul National University College of Medicine, Korea*)
Discussants: Christopher L. Wolfgang (*Department of Surgery, Johns Hopkins University, USA*)
Philippe Levy (*Pole des Maladies de l'Appareil Digestif, Service de Gastroentérologie–Pancreatologie, Hospital Beaujon, France*)
Suresh T. Chari (*Division of Gastroenterology and Hepatology, Mayo Clinic, USA*)

4. **Surveillance of IPMN. How, How Often, and Why?**
Presenter: Philippe Levy (*Pole des Maladies de l'Appareil Digestif, Service de Gastroenterologie–Pancreatologie, Hospital Beaujon, France*)
Discussants: Kenji Yamao (*Department of Gastroenterology, Aichi Cancer Center Hospital, Japan*)
C. Max Schmidt (*Department of Surgery, Indiana University School of Medicine, USA*)
5. **Definition of Malignant IPMN: What do CIS and Minimally Invasive Carcinoma Imply, and are Morphologic Subtypes of Prognostic Significance?**
Presenter #1: “How to Deal with CIS”
Volkan Adsay (*Pathology & Laboratory Medicine, Emory University School of Medicine, USA*)
Presenter #2: “Does Distinction of Gastric, Intestinal, Pancreatobiliary or Oncocytic Forms Have a Role?”
Michio Shimizu (*Department of Pathology, Saitama Medical University, Saitama International Medical Center, Japan*)
Discussants: Philippe Levy (*Pole des Maladies de l'Appareil Digestif, Service de Gastroenterologie–Pancreatologie, Hospital Beaujon, France*)
Koji Yamaguchi (*Department of Surgery 1, University of Occupational and Environmental Health, Japan*)
6. **Carcinoma Derived from IPMN and Carcinoma Concomitant with IPMN: Different or Related Entities?**
Presenter: Koji Yamaguchi (*Department of Surgery 1, University of Occupational and Environmental Health, Japan*)
Discussants: Volkan Adsay (*Pathology & Laboratory Medicine, Emory University School of Medicine, USA*)
Martha Bishop Pitman (*Pathology, Massachusetts General Hospital, Harvard Medical School, USA*)
Wataru Kimura (*Department of Gastroenterological and General Surgery, Yamagata University Faculty of Medicine, Japan*)
7. **What to Do with IPMNs with a Positive Family History of Pancreatic Cancer?**
Presenter: Christopher L. Wolfgang (*Department of Surgery, Johns Hopkins University, USA*)
Discussants: Massimo Falconi (*Department of Surgery, Universita Degli Studi di Verona, Policlinilo GB Rossi, Italy*)
Carlos Fernandez–del Castillo (*Massachusetts General Hospital, USA*)

*Presenters' abstracts are not available for this session. Please refer to moderators' remark on Page 262.

■ IAP Symposium 4

Acute Pancreatitis: Pathogenesis to Treatment

International Pancreatic Research Forum 2010 sponsored by Pancreatic Research Foundation of Japan

JULY 12 (9:00–12:00) Room 2

Moderators: Andrew L. Warshaw (Massachusetts General Hospital, USA)

Yutaka Atomi (Kyorin University Hospital, Japan)

- Keynote** IPSY4-KN **Recent Advance in Pathogenesis of Acute Pancreatitis**
..... Ashok K. Saluja (*Department of Surgery, University of Minnesota, USA*)
- IPSY4-1 **Pancreatic Acinar Cell Death Pathways in Acute Pancreatitis**
..... Masaki Ohmuraya (*Institute of Resource Development and Analysis, Kumamoto University/Priority Organization for Innovation and Excellence, Kumamoto University, Japan*)
- IPSY4-2 **Cell Biology of Pancreatic Proteases**
..... Markus M. Lerch (*Department of Medicine A, Greifswald University, Germany*)
- IPSY4-3 **Investigating Pathobiology of Alcoholic Pancreatitis**
..... Stephen J. Pandol (*Pancreatic Research Group and Southern California Research Center for Alcoholic Liver and Pancreatic Diseases, Yale University and University of California, New Haven and Los Angeles, USA*)
- IPSY4-4 **Pathogenesis of Severe Acute Pancreatitis—Insights from Genetic Studies—**
..... Atsushi Masamune (*Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan*)
- IPSY4-5 **Usefulness of Perfusion CT for Detection of Pancreatic Ischemia in Acute Pancreatitis**
..... Yoshihisa Tsuji (*Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine, Japan*)
- IPSY4-6 **The Role of Antibiotics in the Prevention of Infection in Acute Pancreatitis**
..... Yoshifumi Takeyama (*Department of Surgery, Kinki University, Japan*)
- IPSY4-7 **Surgical Strategies for Acute Pancreatitis**
..... Shuji Isaji (*Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University, Japan*)

■ IAP Symposium 5

Chronic Pancreatitis: Pathogenesis to Treatment

International Pancreatic Research Forum 2010 sponsored by Pancreatic Research Foundation of Japan

JULY 13 (9:30–12:30) Room 2

Moderators: Keiko Shiratori (Tokyo Women's Medical University, Japan)

David C. Whitcomb (University of Pittsburgh, USA)

IPSY5-1 Chronic Pancreatitis: Advances in Understanding the Pathogenesis, Clinical Manifestations, and Diagnosis

..... David C. Whitcomb (*Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh, USA*)

IPSY5-2 Molecular and Cellular Regulation of Pancreatic Duct Function

..... Hiroshi Ishiguro (*Laboratory of Human Nutrition, Nagoya University Graduate School of Medicine, Japan*)

IPSY5-3 Genetic Aspects of Chronic Pancreatitis

..... Heiko Witt (*Department of Paediatrics, Technical University Munich (TUM), Germany*)

IPSY5-4 Genetic Background of Chronic Pancreatitis in Japan

..... Kiyoshi Kume (*Division of Gastroenterology, Tohoku University, Japan*)

IPSY5-5 Role of Stellate Cells in Chronic Pancreatitis

..... Minoti V. Apte (*Pancreatic Research Group, SWS Clinical School, University of New South Wales, Australia*)

IPSY5-6 Regulation of Pancreatic Fibrosis by the Immune System

..... Kyoko Shimizu (*Department of Gastroenterology, Tokyo Women's Medical University, Japan*)

IPSY5-7 Proposal of a New Classification System of Chronic Pancreatitis

..... Manfred V. Singer (*Department of Medicine II, University Medical Centre Mannheim, Germany*)

IPSY5-8 Development of Diagnostic US and EUS of Chronic Pancreatitis

..... Takao Itoi (*Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan*)

IPSY5-9 Endoscopic Strategies for Chronic Pancreatitis: Interventional Management

..... Mel Wilcox (*Division of Gastroenterology and Hepatology, University of Alabama at Birmingham, USA*)

■ IAP&JPS Joint Symposium

Multidisciplinary Approaches to Treatment of Pancreatic Adenocarcinoma

JULY 13 (9:30–12:30) Room 1

Moderators: Dong Wook Choi (Sungkyunkwan University, Korea)
Akimasa Nakao (Nagoya University, Japan)

- JS-1 **A Multicenter Phase II Trial of S-1 and Concurrent Radiotherapy for Locally Advanced Pancreatic Cancer**
..... Michitaka Nagase (*Department of Clinical Oncology, Jichi Medical University, Japan*)
- JS-2 **Gemcitabine and S-1 Combination Therapy as a Second-line Therapy in Patients with Advanced Stage of Pancreatic Cancer**
..... Lingaku Lee (*Gastroenterology, National Kyushu Cancer Center, Japan*)
- JS-3 **Long-term Results of Curative Resection Following Pre-operative Chemoradiation in Patients with Pancreatic Cancer**
..... Sohei Satoi (*Department of Surgery, Kansai Medical University, Japan*)
- JS-4 **Preoperative Full-Dose Gemcitabine Combined with Concurrent 3-D Conformal Radiation and Subsequent Surgery for T3-Pancreatic Cancer**
..... Hidenori Takahashi (*Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan*)
- JS-5 **The Impact of Histological Tumor Destruction after Neoadjuvant Chemoradiotherapy for Locally Advanced Pancreatic Cancer Patients on Disease-free Survival**
..... Yasuhiro Murata (*Department of Hepato-Biliary Pancreatic and Transplant Surgery, Mie University, Japan*)
- JS-6 **Perioperative Chemotherapy for Pancreatic Cancer**
..... Hiroshi Takamori (*Department of Gastroenterological Surgery, Kumamoto University, Japan*)
- JS-7 **Postoperative Adjuvant Treatment for Resected Pancreas Ductal Adenocarcinoma**
..... Dong Wook Choi (*Department of Surgery, Samsung Medical Center, School of Medicine Sungkyunkwan University, Korea*)
- JS-8 **Efficacy of a Novel Postoperative Adjuvant Strategy for Resectable Pancreatic Cancer**
..... Masayuki Sho (*Department of Surgery, Nara Medical University, Japan*)

- JS-9 Multidisciplinary Therapy for Pancreatic Cancer: From Surgery to
Immuno-chemotherapy**
..... Masaji Tani (*Second Department of Surgery, Wakayama Medical
University, Japan*)
- JS-10 Multidisciplinary Approach for Pancreatic Cancer in Korea**
..... Yung-Jue Bang (*Department of Internal Medicine, Seoul National
University Hospital, Seoul, Korea*)

■ JPS Symposium 1

Recent Advances in the Imaging Studies of Pancreatic Diseases

JULY 12 (14:00–16:30) Room 2

Moderators: Koichi Hirata (Sapporo Medical University, Japan)

Yoshiki Hirooka (Nagoya University, Japan)

JPSY1-1 Usefulness of New Ultrasonography Techniques Using Sonazoid in Pancreatic Diseases

..... Atsushi Sofuni (*Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan*)

JPSY1-2 Sonazoid-enhanced US and EUS for Pancreatic Diseases

..... Hirotooshi Iwano (*Department of Gastroenterology and Hepatology, Yamaguchi University of Graduate School of Medicine, Japan*)

JPSY1-3 Dynamic Quantification of Contrast-enhanced Endoscopic Ultrasonography for Diagnosis of Pancreatic Diseases

..... Hiroshi Matsubara (*Department of Gastroenterology, Nagoya University, Japan*)

JPSY1-4 Contrast-enhanced Harmonic Endosonography in Diagnosing Pancreatic Diseases

..... Masayuki Kitano (*Department of Gastroenterology and Hepatology, Kinki University, Japan*)

JPSY1-5 Usefulness of Endoscopic Ultrasound in the Diagnosis of Early Chronic Pancreatitis

..... Atsushi Irisawa (*Gastroenterology, Fukushima Medical University, Japan*)

JPSY1-6 Preoperative Diagnosis of Small Pancreatic Cancer by MDCT, DWI, and EUS

..... Maki Kaneko (*Center for Gastroenterology, Teine-Keijinkai Hospital, Japan*)

JPSY1-7 Intraductal Ultrasonography is Useful for the Assessment of Lateral Spread along the Main Pancreatic Duct in Branch-duct Intraductal Papillary Mucinous Neoplasms of the Pancreas

..... Go Kobayashi (*Department of Gastroenterology, Sendai City Medical Center, Japan*)

- JPSY1-8 CT Perfusion Imaging of the Pancreas**
..... Mi-Suk Park (*Department of Diagnostic Radiology, Yonsei University, Korea*)
- JPSY1-9 Pancreatic Perfusion Analysis of Autoimmune Pancreatitis**
..... Morihisa Hirota (*Division of Gastroenterology, Tohoku University Graduate School of Medicine, Japan*)
- JPSY1-10 Ischemia Penumbra in Early Stage of Severe Acute Pancreatitis**
..... Yoshihisa Tsuji (*Department of Gastroenterology and Hepatology, Kyoto University, Japan*)
- JPSY1-11 Computed Tomography Reflected Endocrine Function of Pancreas**
..... Naoaki Sakata (*Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Tohoku University, Japan*)
- JPSY1-12 Quantitative MR Imaging of the Pancreas: Parametric Exploration**
..... Jeong Min Lee (*Radiology, Seoul National University Hospital, Korea*)
- JPSY1-13 Recent Advances in Intraoperative Diagnostic Techniques for Pancreatic Cancer**
..... Hiroyuki Sugimoto (*Department of Surgery II, Nagoya University, Japan*)
- JPSY1-14 Mass-forming Autoimmune Pancreatitis and Pancreatic Carcinoma: Differential Diagnosis on the Basis of CT, MRCP, and Diffusion-weighted MR Images**
..... Utaroh Motosugi (*Department of Radiology, University of Yamanashi, Japan*)
- JPSY1-15 The Usefulness of PET/CT and Diffusion MRI in Pancreatic Cancer**
..... Makoto Ueno (*Division of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Japan*)

■ JPS Symposium 2

Translational Research for Future Therapy of Pancreatic Cancer

JULY 11 (13:30–16:10) Room 2

Moderators: Tetsuo Ohta (Kanazawa University, Japan)

Toru Furukawa (Tokyo Women's Medical University, Japan)

- Keynote** JPSY2-KN Chromatin-Mediated Regulation of the Tumor Microenvironment Reveals Future Therapies for Pancreatic Cancer
..... Raul Urrutia (*Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, USA*)
- JPSY2-1 Blockade of Tumor-stromal Interaction by Inhibiting CXC Chemokine/CXCR2 Axis as a Potent Therapeutics for Pancreatic Cancer
..... Hideaki Ijichi (*Department of Gastroenterology, University of Tokyo, Japan*)
- JPSY2-2 Heat Shock Protein 90 Inhibitors as a Possible New Candidate for the Treatment of Human Pancreatic Cancer
..... Seiji Adachi (*Department of Gastroenterology and Pharmacology, Gifu University Graduate School of Medicine, Japan*)
- JPSY2-3 Novel Therapeutic Method of HF10 Oncolytic Virus Therapy for Advanced Pancreatic Cancer
..... Hideki Kasuya (*Department of Surgery II, Nagoya University, Japan*)
- JPSY2-4 Remodeling Abnormal Tumor Vasculatures by Transplantation of Vascular Progenitor Cells Reduces Tumor Hypoxia and Drug Resistance in Pancreatic Cancer
..... Junpei Sasajima (*Department of Medicine, Division of Gastroenterology and Hematology/Oncology, Asahikawa Medical College, Japan*)
- JPSY2-5 FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2,3-dioxygenase Expression Predicts the Carcinogenesis of the Pancreas
..... Noritoshi Kobayashi (*Yokohama City University School of Medicine, Japan*)
- JPSY2-6 Hypoxia Induces Tumor Aggressiveness by an Acquired Stem-like Phenotype in Pancreatic Cancer through HIF-1 α signaling
..... Yuichi Hori (*Department of Surgery, Kobe University Graduate School of Medicine, Japan*)

- JPSY2-7 Effect of GSK3 β Inhibition against Gemcitabine-induced Epithelial-mesenchymal Transition and Invasive Ability of Pancreatic Cancer Cells: Its Therapeutic Implication**
..... Takeo Shimasaki (*Department of Medical Oncology, Kanazawa Medical University/Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Japan*)
- JPSY2-8 Peptide Vaccine Therapy for Patients with Advanced Pancreatic Cancer—A Clinical Trial Design from Phase I to Phase II/III for the Development of Therapeutic Cancer Vaccine—**
..... Motoki Miyazawa (*Second Department of Surgery, Wakayama Medical University School of Medicine, Japan*)
- JPSY2-9 Stem Cell Research in Pancreatic Cancer**
..... Si Young Song (*Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, Korea*)
- JPSY2-10 The mTOR Inhibitor RAD001 (Everolimus) Potentiates Cytotoxic Therapy through Tumor Vessel Thrombosis in Xenograft Models of Human Pancreatic Cancer**
..... Atsushi Kida (*Department of Hepato-Biliary-Pancreatic Surgery and Transplantation, Kyoto University, Japan*)
- JPSY2-11 The Function of Rho-kinase in Human Pancreatic Cancer Growth**
..... Masanori Nakashima (*Department of Gastroenterology, Gifu University Graduate School of Medicine, Japan*)
- JPSY2-12 Focused DNA Array (FDA) Using Pancreas Cancer Tissue Obtained by EUS-guided FNA
—For Exploring Possible Predictors of Metastasis—**
..... Reiko Ashida (*Department of Gastroenterology, Graduate School of Medicine, Osaka City University, Japan*)
- JPSY2-13 The Exploration of Novel Strategy for Treatment of Pancreatic Ductal Adenocarcinoma Targeting Angiogenesis with the Use of Genetically Engineered Mouse**
..... Motohisa Tada (*Department of Medicine and Clinical Oncology, Chiba University, Japan*)
- JPSY2-14 Resolution of the Function of Cancer Cells and the Application for Tailor-made Therapy Using Bio-simulation Analysis**
..... Makoto Sunamura (*Molecular Pathology, Tohoku University, Japan*)
- JPSY2-15 The Application of Homeobox Gene MSX2 Down-regulation as a Therapeutic Strategy for Pancreatic Cancer**
..... Kennichi Satoh (*Division of Gastroenterology, Tohoku University, Japan*)

■ JPS Symposium 3

Randomized Controlled Trials against Pancreatic Cancer

JULY 11 (15:30–17:15) Room 1

Moderators: Akihiro Funakoshi (National Kyushu Cancer Center, Japan)
Kyoichi Takaori (Kyoto University, Japan)

- JPSY3-1 Randomized Controlled Trials of Adjuvant Chemotherapy for Resectable Pancreatic Cancer—Experience of the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)
..... Tomoo Kosuge (*National Cancer Center Hospital, Japan*)
- JPSY3-2 Randomized Controlled Multicenter Trial to Establish the Adequate Extent of Resection for Pancreatic Head Cancer in Korea
..... Sun-Whe Kim (*Department of Surgery, Seoul National University Hospital, Korea*)
- JPSY3-3 Randomized Trials of Adjuvant Chemotherapy for Patients with Resected Pancreatic Cancer Using Gemcitabine and/or 5-FU Prodrugs
..... Hideyuki Yoshitomi (*Department of General Surgery, Chiba University, Graduate School of Medicine, Japan*)
- JPSY3-4 Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine Versus S-1 in Patients with Resected Pancreatic Cancer: A Clinical Study of Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)
..... Katsuhiko Uesaka (*Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center Hospital, Japan*)
- JPSY3-5 Randomized Controlled Trials for Pancreatic Surgery—Wakayama Experiences—
..... Hiroki Yamaue (*Second Department of Surgery, Wakayama Medical University School of Medicine, Japan*)
- JPSY3-6 The Final Results of a Randomized Controlled Trial on Surgery Versus Radiochemotherapy for Pancreatic Cancer
..... Ryuichiro Doi (*Department of Surgery, Japanese Red Cross Otsu Hospital/Japan Pancreatic Cancer Study Group, Japan*)

JPSY3-7 Effects of Adjuvant Intra-operative Radiation Therapy after Curative Resection in Pancreatic Cancer Patients: Results of a Randomized Study by 11 Institutions in Japan

..... Taira Kinoshita (*Department of Surgical Oncology, National Cancer Center Hospital East, Japan*)

■ JPS Symposium 4

Management of Complications after Pancreatic Surgery by Endoscopy and Interventional Radiology

JULY 12 (17:00–18:30) Room 1

Moderators: Osamu Ishikawa (Osaka Medical Center for Cancer and
Cardiovascular Diseases, Japan)

Shinichi Egawa (Tohoku University, Japan)

- JPSY4-1 Risk Factors for and Management of Intraoperative Hemorrhage due to Pseudoaneurysm Rupture after Pancreatic and Biliary Surgery
..... Yo-ichi Yamashita (*Department of Surgery, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital, Japan*)
- JPSY4-2 Treatment Strategy and Outcomes of Fistula and Bleeding after Pancreatic Surgery
..... Shunji Nagai (*Department of Gastroenterological Surgery, Nagoya University, Japan*)
- JPSY4-3 Endoscopic Transpapillary Pancreatic Duct Drainage for Treatment and Prevention of Pancreatic Fistula after Pancreatic Surgery
..... Hiroki Kawashima (*Department of Gastroenterology, Nagoya University Graduate School of Medicine, Japan*)
- JPSY4-4 Endoscopic Pancreatic Stenting for Prevention and Treatment of Postoperative Pancreatic Fistula
..... Masanori Sugiyama (*Department of Surgery, Kyorin University, Japan*)
- JPSY4-5 A Multidisciplinary Classification of Invasive Procedures for Treating the Local Complications of Acute Pancreatitis
..... Benjamin P. T. Loveday (*Department of Surgery, University of Auckland/ Pancreas Network of New Zealand, New Zealand*)
- JPSY4-6 EUS-guided Drainage of the Pancreatic Fistula or Pancreatic Duct Dilatation after Resection of the Pancreas: A New Alternative?
..... Manabu Onodera (*Department of Gastroenterology, Hokkaido University, Japan*)
- JPSY4-7 Endoscopic Treatment for Anastomotic Pancreatic Duct Stenosis after Pancreaticoduodenectomy
..... Kei Yane (*Center for Gastroenterology, Teine-Keijinkai Hospital, Japan*)

**JPSY4-8 EUS-guided Treatment in the Cases of Dilated Pancreatic Duct/
Retention Cyst due to Obstruction of Gastro-pancreatic Anastomosis
after Pancreaticoduodenectomy**

..... Tsunehiko Ikeda (*Department of Gastroenterology and Rheumatology,
Fukushima Medical University School of Medicine, Japan*)

JPSY4-9 Interventional Pancreatic Fistulo-jejunostomy

..... Hisashi Gunji (*Gastroenterological Surgery, Chiba Cancer Center
Hospital, Japan*)

■ JPS Video Symposium 1

Cutting Edge Endoscopic Procedures for Diagnosis and Treatment of Pancreatic Diseases

JULY 11 (13:30–15:20) Room 1

Moderators: Teruo Nakamura (Hirosaki University, Japan)

Hiroyuki Maguchi (Teine-Keijinkai Hospital, Japan)

VS1-1 Endoscopic Ultrasound-guided Drainage for Pancreatic Diseases
..... Ken Kamata (*Department of Gastroenterology and Hepatology, Kinki University, Japan*)

VS1-2 The Role of Interventional EUS for Pancreatic Diseases
..... Rei Suzuki (*Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Japan*)

VS1-3 Interventional EUS for Pancreatic Disease
..... Kumiko Taba (*Gastroenterology and Hepatology, Yamaguchi University, Japan*)

**VS1-4 How to Treat the Pancreatic Pseudocyst.
Is Endoscopic Transpapillary Drainage the Best Treatment?**
..... Tadao Tsuji (*Gastroenterology, Saitama City Hospital, Japan*)

VS1-5 The Value of Cytology Using Endoscopic Naso-pancreatic Drainage (ENPD) for Early Diagnosis of Pancreatic Cancer
..... Tomohiro Iiboshi (*Center for Gastroendoscopy, Onomichi General Hospital, Japan*)

VS1-6 Endoscopic Treatment via the Minor Papilla by the Rendezvous Technique
..... Manabu Osanai (*Center for Gastroenterology, Teine-Keijinkai Hospital, Japan*)

VS1-7 A Novel Technique for Treating Infected Pancreatic Necrosis: Endoscopic Necrosectomy Based on the NOTES Approach
..... Ichiro Yasuda (*First Department of Internal Medicine, Gifu University Hospital, Japan*)

VS1-8 Laparoscopic Ultrasonography-guided Biopsy for Pathological Diagnosis in Advanced Unresectable Pancreatic Cancer
..... Kosei Maemura (*Department of Surgical Oncology and Digestive Surgery, Kagoshima University, Japan*)

VS1-9 Endoscopic Surgery for Islet Cell Tumor of the Pancreas
..... Makoto Hiroi (*Department of Surgery, Nippon Medical School, Japan*)

■ JPS Video Symposium 2

Surgical Treatment of Pancreatic Neoplasms—From Limited Surgery to Extended Surgery

JULY 12 (14:00–17:00) Room 1

Moderators: Satoshi Kondo (Hokkaido University, Japan)

Hiroki Yamaue (Wakayama Medical University, Japan)

- VS2-1 Significance of Dissection Including the Root of the Mesentery for Pancreatic Head Carcinomas Arising from the Ventral Pancreas Domain
..... Hirohisa Kitagawa (*Gastroenterologic Surgery, Kanazawa University, Japan*)
- VS2-2 Non-touch Isolated Pancreaticoduodenectomy with a Mesenteric Approach for Pancreatic Head Cancer
..... Mitsuro Kanda (*Department of Surgery II, Nagoya University, Japan*)
- VS2-3 Pancreaticoduodenectomy Combined with Portal Vein Resection and Reconstruction for Pancreas Head Cancer
..... Atsushi Kato (*Department of General Surgery, Chiba University, Japan*)
- VS2-4 Oblique Transection of the Pancreas Head in Extended Distal Pancreatectomy with en Bloc Celiac Axis Resection (DP-CAR) for Advanced Pancreas Body Cancer
..... Satoshi Hirano (*Department of Surgical Oncology, Hokkaido University, Japan*)
- VS2-5 Is Limited Pancreatic Resection Feasible for Renal Cell Carcinoma Metastatic to the Pancreas?
..... Yasutoshi Kimura (*Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University, Japan*)
- VS2-6 Pancreatic Head Resection with Segmental Duodenectomy (PHRSD) for Intraductal Papillary Mucinous Neoplasms (IPMN) of the Pancreatic Head
..... Shuji Nomoto (*Department of Surgery II, Nagoya University, Japan*)
- VS2-7 How I Do It—Pancreaticojejunostomy (Duct to Mucosa Anastomosis)
..... Hong-Jin Kim (*Department of Surgery, Yeungnam University, Korea*)

- VS2-8 Laparoscopic Spleen Preserving Distal Pancreatectomy with Special Reference to Vessel Preservation**
..... Masafumi Nakamura (*Department of Surgery and Oncology, Kyushu University, Japan*)
- VS2-9 Laparoscopic Distal Pancreatectomy in Our Institution**
..... Yoshiharu Nakamura (*Department of Surgery, Nippon Medical School, Japan*)
- VS2-10 Laparoscope-assisted Central Pancreatectomy**
..... Seiko W. Hirono (*Second Department of Surgery, Wakayama Medical University, School of Medicine, Japan*)
- VS2-11 HALS-DP as a Standard Method for Distal Pancreatic Tumors**
..... Masayuki Tori (*Surgery, Osaka Police Hospital, Japan*)
- VS2-12 Usefulness of Hand-assisted Laparoscopic Distal Pancreatectomy for Benign and Low-grade Malignant Tumors of the Pancreas**
..... Ippei Matsumoto (*Department of Hepato-Biliary-Pancreatic Surgery, Kobe University, Japan*)
- VS2-13 Minimally Invasive Surgery for Pancreatic Disease**
..... Han Ho-Seong (*Surgery, Seoul National University/Surgery, Seoul National University Bundang Hospital, Korea*)
- VS2-14 Laparoscopic Pancreaticoduodenectomy—Can LPD be One of Therapeutic Options for Pancreatic Neoplasms? —**
..... Akihiro Cho (*Division of Gastroenterology, Chiba Cancer Center Hospital, Japan*)
- VS2-15 Robot-assisted Function-preserving Minimally Invasive Pancreatectomy in Benign and Borderline Malignant Tumor of the Pancreas**
..... Chang Moo Kang (*Department of Surgery, Division of Biliopancreas, Yonsei University College of Medicine, Korea*)